Brief: Abbott Reaches Agreements To Resolve A Portion Of Litigation Involving Its Specialty Formulas For Preterm Infants
20/08/2026 21:30
BRIEF-Abbott Reaches Agreements To Resolve A Portion Of Litigation Involving Its Specialty Formulas For Preterm Infants Aug 20 (Reuters) - Abbott Laboratories ABT.N:
ABBOTT REACHES AGREEMENTS TO RESOLVE A PORTION OF LITIGATION INVOLVING ITS SPECIALTY FORMULAS FOR PRETERM INFANTS
ABBOTT - REACHES AGREEMENTS TO RESOLVE GILL CASE AND 2,000 RELATED CLAIMS
ABBOTT - TO PAY ABOUT $670 MILLION TO RESOLVE GILL CASE AND NEC CLAIMS
ABBOTT - ABOUT 1,700 LAWSUITS REMAIN PENDING INVOLVING CLAIMS FOR 12,700 INFANTS
ABBOTT REACHES AGREEMENTS TO RESOLVE A PORTION OF LITIGATION INVOLVING ITS SPECIALTY FORMULAS FOR PRETERM INFANTS
Source text: ID:nPn5Jcys9a
Further company coverage: ABT.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbott Laboratories
See all newsBrief: Abbott Announces Availability Of Panbio Covid-19/Flu A&B Self-Test In Canada
Perrigo to sell infant formula business to MeridianMade for up to $175 million
Brief: Abbott Initiates Pivotal Trial For Cephea™ Device, An Innovative Treatment For Mitral Heart Valve Disease
Corrected: German startup NVision shows new path to quantum computing chips in Nature paper
Brief: Abbott Receives FDA Approval For First Device To Treat Leaks After Heart Valve Replacement